Luminex
DiaSorin 2022 Revenues Grow 10 Percent
For 2023, total revenues are expected to decline 14 percent year over year, and COVID-19 revenues are expected to be down 75 percent to €60 million.
DiaSorin Gets FDA 510(k) for Molecular COVID-19/Flu Assay
The real-time RT-PCR Simplexa COVID-19 & Flu A/B Direct assay is designed for use on the company's Liaison MDX instrument, with results in about one hour.
DiaSorin Selling Luminex Flow Cytometry Business to Cytek Biosciences for $46.5M
The cash deal for the DiaSorin subsidiary's flow cytometry and imaging business adds to Cytek's technological capabilities and global reach.
New Products Posted to GenomeWeb: Qiagen, Boston Heart Diagnostics, Bio-Techne, More
New products posted to GenomeWeb for the week of Aug. 15, 2022.
Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19
Results are generated in a single workflow from a patient sample, which enables rapid detection for the differential diagnosis of a single pathogen.